Pfizer's $90b Lipitor Vs LL: The largest buy-ou
Post# of 154287
(Total Views: 707)
Posted On: 05/31/2025 12:43:13 AM
Pfizer's $90b Lipitor Vs LL:
The largest buy-out in pharma history by Pfizer.
Why ? For full iP rights.
___
*Pfizer started a hostile takeover of Warner-Lambert in December 1999. One of the principle reasons being to secure the full rights to Warner-Lambert's Lipitor (atorvastatin), which Pfizer already co-promoted with Warner-Lambert.
___
Can, not, overlook our patent value.
Ladies of Leronlimab have validated our iP as an Exclusive & Non-exclusive Right(s).
Even exclusive mfgr'ing rights = serious profits.
In 2000, Pfizer paid $90b for Warner-Lambert to fully gain the remaining 11 yrs of patent rights out to 2011.
The two had actually co-marketed Lipitor.
Lipitor of course has SAE's & drug-drug interactions, with the YOY sales & total market projections are puny, i mean puny in comparison to just our oncology focus.
___
*Atorvastatin, marketed as Lipitor, was a blockbuster drug, peaking at almost $13 billion in sales in 2006. While sales have declined since the patent expired in 2011, with most sales now coming from emerging markets like China, Lipitor still generates roughly $2 billion per year. The global atorvastatin market is estimated to be around US$4.6 billion in 2024 and is projected to grow to US$6.05 billion by 2031.
*Atorvastatin belongs to a class of drugs called statins or HMG-CoA reductase inhibitors.
It works by inhibiting an enzyme in the liver that's crucial for cholesterol production.
By reducing cholesterol production and increasing the liver's ability to remove LDL cholesterol, Atorvastatin helps lower LDL ("bad" cholesterol and triglycerides, while also slightly increasing HDL ("good" cholesterol.
___
For me,
a buy-out if only VERY north of $90b @ largest ever in the pharma industry.
Or...we build a Leronlimab j/v empire unlike no other.
The largest buy-out in pharma history by Pfizer.
Why ? For full iP rights.
___
*Pfizer started a hostile takeover of Warner-Lambert in December 1999. One of the principle reasons being to secure the full rights to Warner-Lambert's Lipitor (atorvastatin), which Pfizer already co-promoted with Warner-Lambert.
___
Can, not, overlook our patent value.
Ladies of Leronlimab have validated our iP as an Exclusive & Non-exclusive Right(s).
Even exclusive mfgr'ing rights = serious profits.
In 2000, Pfizer paid $90b for Warner-Lambert to fully gain the remaining 11 yrs of patent rights out to 2011.
The two had actually co-marketed Lipitor.
Lipitor of course has SAE's & drug-drug interactions, with the YOY sales & total market projections are puny, i mean puny in comparison to just our oncology focus.
___
*Atorvastatin, marketed as Lipitor, was a blockbuster drug, peaking at almost $13 billion in sales in 2006. While sales have declined since the patent expired in 2011, with most sales now coming from emerging markets like China, Lipitor still generates roughly $2 billion per year. The global atorvastatin market is estimated to be around US$4.6 billion in 2024 and is projected to grow to US$6.05 billion by 2031.
*Atorvastatin belongs to a class of drugs called statins or HMG-CoA reductase inhibitors.
It works by inhibiting an enzyme in the liver that's crucial for cholesterol production.
By reducing cholesterol production and increasing the liver's ability to remove LDL cholesterol, Atorvastatin helps lower LDL ("bad" cholesterol and triglycerides, while also slightly increasing HDL ("good" cholesterol.
___
For me,
a buy-out if only VERY north of $90b @ largest ever in the pharma industry.
Or...we build a Leronlimab j/v empire unlike no other.
(3)
(0)